Vanguard reports 4.87% stake in OnKure

OnKure Therapeutics Inc received an updated institutional ownership report from The Vanguard Group, which beneficially owns 626,593 shares of OnKure common stock, representing 4.87% of the class as of the reported date.

Rhea-AI Filing Summary

OnKure Therapeutics Inc received an updated institutional ownership report from The Vanguard Group, which beneficially owns 626,593 shares of OnKure common stock, representing 4.87% of the class as of the reported date. Vanguard reports no sole voting or dispositive power, but shared voting power over 44,116 shares and shared dispositive power over all 626,593 shares.

The filing notes that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries or divisions are expected to report beneficial ownership separately while pursuing the same investment strategies. Vanguard states the securities are held in the ordinary course of business for its clients and not to change or influence control of OnKure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does The Vanguard Group’s Schedule 13G/A reveal about its OKUR stake?

The Vanguard Group reports beneficial ownership of 626,593 OnKure (OKUR) shares, equal to 4.87% of the common stock. The firm has shared voting power over 44,116 shares and shared dispositive power over all 626,593 shares, held for clients in the ordinary course of business.

How many OnKure Therapeutics (OKUR) shares does Vanguard beneficially own?

Vanguard beneficially owns 626,593 shares of OnKure Therapeutics common stock. This position represents 4.87% of the outstanding class, with no sole voting or dispositive power, but shared voting over 44,116 shares and shared dispositive authority over the full 626,593 shares.

What voting and dispositive powers does Vanguard report over OKUR shares?

Vanguard reports shared voting power for 44,116 OnKure (OKUR) shares and shared dispositive power for 626,593 shares. It reports zero sole voting and zero sole dispositive power, indicating decisions are made collectively or for client accounts rather than unilaterally by Vanguard.

Why did Vanguard mention an internal realignment in this OKUR filing?

Vanguard notes a January 12, 2026 internal realignment affecting portfolio management and proxy voting. After this change, certain subsidiaries or business divisions are expected to report beneficial ownership in OnKure and other issuers separately, while continuing the same investment strategies used before the realignment.

Are Vanguard’s OnKure (OKUR) holdings intended to influence control of the company?

Vanguard certifies its OnKure holdings are acquired and held in the ordinary course of business, not to influence control. The firm states the securities are not held in connection with any transaction aimed at changing or influencing control of OnKure Therapeutics.

Who ultimately benefits from Vanguard’s 626,593-share OKUR position?

Vanguard states its clients benefit from the 626,593 OnKure (OKUR) shares it reports. These clients include registered investment companies and other managed accounts, which have rights to dividends or sale proceeds, with no single other person holding more than 5% through these securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/30/2026 - 02:21 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

OnKure Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

68277Q105

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 68277Q105

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 44,116.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 626,593.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

626,593.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.87 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: OnKure Therapeutics Inc
(b)	Address of issuer's principal executive offices: 6707 Winchester Circle, Suite 400, Boulder, CO, 80301
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 68277Q105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 626593
(b)	Percent of class: 4.87 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 44116
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 626593
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026